Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin PK in Neonates and Infants
NCT02688790Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Apr 2016
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dalbavancin in bacterial infection (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Plasma concentration of dalbavancin and Number of patients experiencing a treatment emergent adverse event. Started Apr 2016; status: terminated.
02
Drugs
dalbavancin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02688790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688790.